Clinical Trial Update: Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating temozolomide in young patients with high-risk relapsed or refractory neuroblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Temozolomide (Temozolomide)

Snippet

Sponsor: Children's Cancer and Leukaemia Group | Conditions: Neuroblastoma | Phase 2 | Status: COMPLETED